Divi's Laboratories
Market Cap
₹821.2b
Last Updated
2020/10/20 12:36 UTC
Data Sources
Company Financials +
Executive Summary
Divi's Laboratories Limited manufactures and sells generic active pharmaceutical ingredients (APIs) and intermediates for in the United States, Asia, Europe, and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with solid track record and pays a dividend.
Similar Companies
Share Price & News
How has Divi's Laboratories's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DIVISLAB's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-1.5%
DIVISLAB
-2.9%
IN Life Sciences
-0.6%
IN Market
1 Year Return
77.7%
DIVISLAB
64.5%
IN Life Sciences
2.2%
IN Market
Return vs Industry: DIVISLAB exceeded the Indian Life Sciences industry which returned 64.5% over the past year.
Return vs Market: DIVISLAB exceeded the Indian Market which returned 2.2% over the past year.
Shareholder returns
| DIVISLAB | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.5% | -2.9% | -0.6% |
| 30 Day | -7.5% | -6.3% | 0.2% |
| 90 Day | 36.8% | 33.1% | 6.7% |
| 1 Year | 79.0%77.7% | 65.4%64.5% | 3.9%2.2% |
| 3 Year | 264.9%255.7% | 168.9%164.2% | 2.6%-2.4% |
| 5 Year | 195.4%181.7% | 170.9%160.5% | 41.3%30.8% |
Price Volatility Vs. Market
How volatile is Divi's Laboratories's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Investors Who Bought Divi's Laboratories (NSE:DIVISLAB) Shares Three Years Ago Are Now Up 270%4 weeks ago | Simply Wall St
Divi's Laboratories Limited's (NSE:DIVISLAB) Stock's On An Uptrend: Are Strong Financials Guiding The Market?1 month ago | Simply Wall St
Is Divi's Laboratories (NSE:DIVISLAB) A Risky Investment?Valuation
Is Divi's Laboratories undervalued compared to its fair value and its price relative to the market?
51.45x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: DIVISLAB (₹3093.4) is trading above our estimate of fair value (₹597.2)
Significantly Below Fair Value: DIVISLAB is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: DIVISLAB is poor value based on its PE Ratio (51.4x) compared to the IN Life Sciences industry average (41.4x).
PE vs Market: DIVISLAB is poor value based on its PE Ratio (51.4x) compared to the Indian market (16.3x).
Price to Earnings Growth Ratio
PEG Ratio: DIVISLAB is poor value based on its PEG Ratio (3.2x)
Price to Book Ratio
PB vs Industry: DIVISLAB is overvalued based on its PB Ratio (11.2x) compared to the IN Life Sciences industry average (1.8x).
Next Steps
Future Growth
How is Divi's Laboratories forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
16.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DIVISLAB's forecast earnings growth (16.2% per year) is above the savings rate (7.2%).
Earnings vs Market: DIVISLAB's earnings (16.2% per year) are forecast to grow slower than the Indian market (25.5% per year).
High Growth Earnings: DIVISLAB's earnings are forecast to grow, but not significantly.
Revenue vs Market: DIVISLAB's revenue (17.5% per year) is forecast to grow faster than the Indian market (11.6% per year).
High Growth Revenue: DIVISLAB's revenue (17.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DIVISLAB's Return on Equity is forecast to be high in 3 years time (23.8%)
Next Steps
Past Performance
How has Divi's Laboratories performed over the past 5 years?
8.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DIVISLAB has high quality earnings.
Growing Profit Margin: DIVISLAB's current net profit margins (26.8%) are higher than last year (26.5%).
Past Earnings Growth Analysis
Earnings Trend: DIVISLAB's earnings have grown by 8.4% per year over the past 5 years.
Accelerating Growth: DIVISLAB's earnings growth over the past year (17.6%) exceeds its 5-year average (8.4% per year).
Earnings vs Industry: DIVISLAB earnings growth over the past year (17.6%) underperformed the Life Sciences industry 17.7%.
Return on Equity
High ROE: DIVISLAB's Return on Equity (21.8%) is considered high.
Next Steps
Financial Health
How is Divi's Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: DIVISLAB's short term assets (₹46.8B) exceed its short term liabilities (₹9.3B).
Long Term Liabilities: DIVISLAB's short term assets (₹46.8B) exceed its long term liabilities (₹3.0B).
Debt to Equity History and Analysis
Debt Level: DIVISLAB's debt to equity ratio (0.5%) is considered satisfactory.
Reducing Debt: DIVISLAB's debt to equity ratio has reduced from 0.8% to 0.5% over the past 5 years.
Debt Coverage: DIVISLAB's debt is well covered by operating cash flow (3615.6%).
Interest Coverage: DIVISLAB's interest payments on its debt are well covered by EBIT (321.2x coverage).
Balance Sheet
Next Steps
Dividend
What is Divi's Laboratories's current dividend yield, its reliability and sustainability?
0.52%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: DIVISLAB's dividend (0.52%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.57%).
High Dividend: DIVISLAB's dividend (0.52%) is low compared to the top 25% of dividend payers in the Indian market (2.29%).
Stability and Growth of Payments
Stable Dividend: DIVISLAB's dividends per share have been stable in the past 10 years.
Growing Dividend: DIVISLAB's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (26.6%), DIVISLAB's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: DIVISLAB's dividends in 3 years are forecast to be well covered by earnings (26.4% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
7.1yrs
Average board tenure
CEO
Kiran Divi (44 yo)
0.75
Tenure
₹183,500,000
Compensation
Dr. Kiran Satchandra Divi has been the Chief Executive Officer of Divi's Laboratories Limited since January 4, 2020. Dr. Divi has been an Whole-time Director at Divi's Laboratories Limited and its and ser ...
CEO Compensation Analysis
Compensation vs Market: Kiran's total compensation ($USD2.50M) is above average for companies of similar size in the Indian market ($USD1.42M).
Compensation vs Earnings: Kiran's compensation has been consistent with company performance over the past year.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Whole-Time Director | 0.75yr | ₹183.50m | 20.34% ₹ 167.0b | |
| Managing Director & Director | 30yrs | ₹523.60m | 2.85% ₹ 23.4b | |
| Executive Director | 26yrs | ₹269.10m | 0.12% ₹ 999.4m | |
| Director of Projects & Whole-Time Director | 26yrs | ₹9.90m | 0.13% ₹ 1.0b | |
| Whole-time Director & Director of Commercial | 3.33yrs | ₹50.30m | 20.34% ₹ 167.0b | |
| Non-Executive Independent Director | 19.58yrs | ₹2.00m | 0.00015% ₹ 1.2m | |
| Non-Executive Independent Director | 7.92yrs | ₹2.40m | no data | |
| Non-Executive Independent Director | 6.33yrs | ₹2.00m | no data | |
| Independent Non-Executive Chairman | 0.50yr | ₹2.40m | no data | |
| Independent Additional Director | 3.25yrs | ₹2.00m | no data | |
| Independent Director | 1.58yrs | ₹1.20m | no data | |
| Non-Executive Independent Director | 0.75yr | no data | no data |
7.1yrs
Average Tenure
67yo
Average Age
Experienced Board: DIVISLAB's board of directors are considered experienced (7.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DIVISLAB insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Divi's Laboratories Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Divi's Laboratories Limited
- Ticker: DIVISLAB
- Exchange: NSEI
- Founded: 1990
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹821.201b
- Shares outstanding: 265.47m
- Website: https://www.divislabs.com
Number of Employees
Location
- Divi's Laboratories Limited
- Divi Towers
- 1-72/23(P)/DIVIS/303
- Hyderabad
- Andhra Pradesh
- 500032
- India
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 532488 | BSE (Mumbai Stock Exchange) | Yes | Equity Shares | IN | INR | Mar 2003 |
| DIVISLAB | NSEI (National Stock Exchange of India) | Yes | Equity Shares | IN | INR | Mar 2003 |
Biography
Divi's Laboratories Limited manufactures and sells generic active pharmaceutical ingredients (APIs) and intermediates for in the United States, Asia, Europe, and internationally. The company also undertake ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/20 12:36 |
| End of Day Share Price | 2020/10/19 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2020/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.